Literature DB >> 1672872

c-erbB-2 expression in different histological types of invasive breast carcinoma.

S Soomro1, S Shousha, P Taylor, H M Shepard, M Feldmann.   

Abstract

Sections of 149 breast carcinomas were examined for the over-expression of c-erbB-2 oncoprotein using the avidin-biotin immunoperoxidase technique and two different specific antibodies. These included the polyclonal antibody 21N and the monoclonal antibody 4D5. The tumours were divided into two main groups. The first included 75 cases of invasive ductal and classic invasive lobular carcinomas. The second group consisted of 74 cases with histological types known to have a good prognosis, including mucinous, alveolar variant of invasive lobular, medullary, tubular, cribriform and papillary carcinomas. Fifteen (20%) tumours of the first group were positive with the two antibodies. Fourteen of these were of the ductal type and one was a mixed invasive ductal and lobular carcinoma. Ten of the pure ductal cases had areas of comedo carcinoma. The intraductal elements in a further tumour were positively stained with 21N antibody only. None of the second group of tumours, which included histological types known to have good prognosis, stained with 4D5, although one mucinous carcinoma was positively stained with 21N. These findings suggest that in invasive breast carcinoma immunostaining for c-erbB-2 is mainly seen in a subgroup of ductal tumours, and that almost all other histological types, especially those associated with good prognosis, lack this expression.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1672872      PMCID: PMC496939          DOI: 10.1136/jcp.44.3.211

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  38 in total

1.  Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease.

Authors:  D J Zhou; H Ahuja; M J Cline
Journal:  Oncogene       Date:  1989-01       Impact factor: 9.867

2.  Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis.

Authors:  J M Varley; J E Swallow; W J Brammar; J L Whittaker; R A Walker
Journal:  Oncogene       Date:  1987       Impact factor: 9.867

3.  c-erbB-2 oncoprotein expression in mammary and extramammary Paget's disease: an immunohistochemical study.

Authors:  L Keatings; J Sinclair; C Wright; I P Corbett; C Watchorn; C Hennessy; B Angus; T Lennard; C H Horne
Journal:  Histopathology       Date:  1990-09       Impact factor: 5.087

4.  Proto-oncogene abnormalities in human breast cancer: correlations with anatomic features and clinical course of disease.

Authors:  M J Cline; H Battifora; J Yokota
Journal:  J Clin Oncol       Date:  1987-07       Impact factor: 44.544

5.  The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen.

Authors:  A L Schechter; D F Stern; L Vaidyanathan; S J Decker; J A Drebin; M I Greene; R A Weinberg
Journal:  Nature       Date:  1984 Dec 6-12       Impact factor: 49.962

6.  Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer.

Authors:  D Zhou; H Battifora; J Yokota; T Yamamoto; M J Cline
Journal:  Cancer Res       Date:  1987-11-15       Impact factor: 12.701

Review 7.  Correlation of erbB-2 gene amplification with low levels of estrogen and/or progesterone receptors in primary breast cancer: do erbB-2 products delineate hormone-independent tumors?

Authors:  M Roux-Dosseto; S Romain; N Dussault; P M Martin
Journal:  Biomed Pharmacother       Date:  1989       Impact factor: 6.529

8.  The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor.

Authors:  A L Schechter; M C Hung; L Vaidyanathan; R A Weinberg; T L Yang-Feng; U Francke; A Ullrich; L Coussens
Journal:  Science       Date:  1985-09-06       Impact factor: 47.728

9.  An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma.

Authors:  D M Barnes; G A Lammie; R R Millis; W L Gullick; D S Allen; D G Altman
Journal:  Br J Cancer       Date:  1988-10       Impact factor: 7.640

10.  c-erbB-2 expression in benign and malignant breast disease.

Authors:  B A Gusterson; L G Machin; W J Gullick; N M Gibbs; T J Powles; C Elliott; S Ashley; P Monaghan; S Harrison
Journal:  Br J Cancer       Date:  1988-10       Impact factor: 7.640

View more
  10 in total

1.  Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus.

Authors:  J Jankowski; G Coghill; D Hopwood; K G Wormsley
Journal:  Gut       Date:  1992-08       Impact factor: 23.059

Review 2.  HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer.

Authors:  Kazi M Ahmed; Ning Cao; Jian Jian Li
Journal:  Anticancer Res       Date:  2006 Nov-Dec       Impact factor: 2.480

3.  ErbB-2 oncoprotein overexpression in breast carcinoma: inverse correlation with biochemically- and immunohistochemically-determined hormone receptors.

Authors:  A A Keshgegian
Journal:  Breast Cancer Res Treat       Date:  1995-08       Impact factor: 4.872

Review 4.  Protein kinases in human breast cancer.

Authors:  W G Cance; E T Liu
Journal:  Breast Cancer Res Treat       Date:  1995-07       Impact factor: 4.872

5.  Epidermal growth factor receptor immunohistochemistry in different histological types of infiltrating breast carcinoma.

Authors:  M Martinazzi; F Crivelli; C Zampatti; S Martinazzi
Journal:  J Clin Pathol       Date:  1993-11       Impact factor: 3.411

6.  c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma.

Authors:  J E Somerville; L A Clarke; J D Biggart
Journal:  J Clin Pathol       Date:  1992-01       Impact factor: 3.411

7.  Antiproliferative and proapoptotic activities of Sea Cucumber H. Leucospilota extract on breast carcinoma cell line (SK-BR-3).

Authors:  Mostafa Khaledi; Bahman Moradipoodeh; Rahim Moradi; Maryam Abedini Baghbadorani; Masoud Mahdavinia
Journal:  Mol Biol Rep       Date:  2022-01-19       Impact factor: 2.316

8.  Evolving concepts in breast lobular neoplasia and invasive lobular carcinoma, and their impact on imaging methods.

Authors:  Tatiane M G Oliveira; Jorge Elias; Andrea F Melo; Sara R Teixeira; Salomão C Filho; Larissa M Gonçalves; Francesca M Faria; Daniel G Tiezzi; Jurandyr M Andrade; Valdair Muglia
Journal:  Insights Imaging       Date:  2014-03-16

Review 9.  Breast cancer adaptive resistance: HER2 and cancer stem cell repopulation in a heterogeneous tumor society.

Authors:  Nadire Duru; Demet Candas; Guochun Jiang; Jian Jian Li
Journal:  J Cancer Res Clin Oncol       Date:  2013-08-30       Impact factor: 4.553

10.  Prognostic significance of c-erbB-2 expression in node negative breast cancer.

Authors:  S Bianchi; M Paglierani; G Zampi; G Cardona; L Cataliotti; R Bonardi; S Ciatto
Journal:  Br J Cancer       Date:  1993-03       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.